WHAT IS CLAIMED IS:

1. A compound of the structure:



or a pharmaceutically acceptable salt thereof, wherein

z is a single or double bond;

A is

a) an aryl ring, wherein any stable aryl ring atom is independently unsubstituted or substituted with

1) halogen,
2) NO_2,
3) CN,
4) $CR^{46}=C(R^{47}R^{48})_2$,
5) $C\equiv C\ R^{46}$,
6) $(CR^iR^j)_rOR^{46}$,
7) $(CR^iR^j)_rN(R^{46}R^{47})$,
8) $(CR^iR^j)_r\ C(O)R^{46}$,
9) $(CR^iR^j)_r\ C(O)OR^{46}$,
10) $(CR^iR^j)_rR^{46}$,
11) $(CR^iR^j)_r\ S(O)_{0-2}R^{61}$,
12) $(CR^iR^j)_r\ S(O)_{0-2}N(R^{46}R^{47})$,
13) $OS(O)_{0-2}R^{61}$,
14) $N(R^{46})C(O)R^{47}$,
15) $N(R^{46})S(O)_{0-2}R^{61}$,
16) $(CR^iR^j)_rN(R^{46})R^{61}$,
17) $(CR^iR^j)_rN(R^{46})R^{61}OR^{47}$,
18) $(CR^iR^j)_rN(R^{46})(CR^kR^l)_sC(O)N(R^{47}R^{48})$,
19) $N(R^{46})(CR^iR^j)_rR^{61}$,
20) $N(R^{46})(CR^iR^j)_rN(R^{47}R^{48})$,
21) $(CR^iR^j)_rC(O)N(R^{47}R^{48})$, or

22) oxo, or

b) a heteroaryl ring selected from the group consisting of
a 5-membered unsaturated monocyclic ring with 1, 2, 3 or 4 heteroatom ring atoms selected from the group consisting or N, O or S,
a 6-membered unsaturated monocyclic ring with 1, 2, 3 or 4 heteroatom ring atoms selected from the group consisting N, O and S, and
a 9- or 10-membered unsaturated bicyclic ring with 1, 2, 3 or 4 heteroatom ring atoms selected from the group consisting or N, O or S;

wherein any stable S heteroaryl ring atom is unsubstituted or mono- or di-substituted with oxo, and any stable C or N heteroaryl ring atom is independently unsubstituted or substituted with

1) halogen,
2) NO_2,
3) CN,
4) $CR^{46}=C(R^{47}R^{48})_2$,
5) $C\equiv CR^{46}$,
6) $(CR^iR^j)_rOR^{46}$,
7) $(CR^iR^j)_rN(R^{46}R^{47})$,
8) $(CR^iR^j)_r C(O)R^{46}$,
9) $(CR^iR^j)_r C(O)OR^{46}$,
10) $(CR^iR^j)_rR^{46}$,
11) $(CR^iR^j)_r S(O)_{0-2}R^{61}$,
12) $(CR^iR^j)_r S(O)_{0-2}N(R^{46}R^{47})$,
13) $OS(O)_{0-2}R^{61}$,
14) $N(R^{46})C(O)R^{47}$,
15) $N(R^{46})S(O)_{0-2}R^{61}$,
16) $(CR^iR^j)_rN(R^{46})R^{61}$,
17) $(CR^iR^j)_rN(R^{46})R^{61}OR^{47}$,
18) $(CR^iR^j)_rN(R^{46})(CR^kR^l)_sC(O)N(R^{47}R^{48})$,
19) $N(R^{46})(CR^iR^j)_rR^{61}$,
20) $N(R^{46})(CR^iR^j)_rN(R^{47}R^{48})$,
21) $(CR^iR^j)_rC(O)N(R^{47}R^{48})$, or
22) oxo;

R^2, R^8, R^9 and R^{10} are independently selected from:

1) hydrogen,
2) halogen,
3) NO_2,
4) CN,
5) $CR^{43}=C(R^{44}R^{45})$,
6) $C\equiv CR^{43}$,
7) $(CR^eR^f)_pOR^{43}$,
8) $(CR^eR^f)_pN(R^{43}R^{44})$,
9) $(CR^eR^f)_pC(O)R^{43}$,
10) $(CR^eR^f)_pC(O)OR^{43}$,
11) $(CR^eR^f)_pR^{43}$,
12) $(CR^eR^f)_pS(O)_{0-2}R^{60}$,
13) $(CR^eR^f)_pS(O)_{0-2}N(R^{43}R^{44})$,
14) $OS(O)_{0-2}R^{60}$,
15) $N(R^{43})C(O)R^{44}$,
16) $N(R^{43})S(O)_{0-2}R^{60}$,
17) $(CR^eR^f)_pN(R^{43})R^{60}$,
18) $(CR^eR^f)_pN(R^{43})R^{60}OR^{44}$,
19) $(CR^eR^f)_pN(R^{43})(CR^gR^h)_qC(O)N(R^{44}R^{45})$,
20) $N(R^{43})(CR^eR^f)_pR^{60}$,
21) $N(R^{43})(CR^eR^f)_pN(R^{44}R^{45})$, and
22) $(CR^eR^f)_pC(O)N(R^{43}R^{44})$,

or R^2 and R^8 are independently as defined above, and R^9 and R^{10}, together with the atoms to which they are attached, form the ring



, where R^m is C_{1-6}alkyl;

R^1 is selected from the group consisting of

1) hydrogen,
2) $(CR^aR^b)_nR^{40}$
3) $(CR^aR^b)_nOR^{40}$,
4) $(CR^aR^b)_nN(R^{40}R^{41})$,
5) $(CR^aR^b)_nN(R^{40})C(O)OR^{41}$,
6) $(CR^aR^b)_nN(R^{40})(CR^cR^d)_2N(R^{41})C(O)R^{49}$,
7) C_{3-8} cycloalkyl,

8) $(CR^aR^b)_nC(O)OR^{40}$,
9) $(CR^aR^b)_nN(R^{40})(CR^cR^d)_{1-3}R^{41}$,
10) $(CR^aR^b)_nS(O)_{0-2}R^6$,
11) $(CR^aR^b)_nS(O)_{0-2}N(R^{40}R^{41})$,
12) $(CR^aR^b)_nN(R^{40})R^6OR^{41}$,
13) $(CR^aR^b)_nN(R^{40})(CR^cR^d)_{0-6}C(O)N(R^{41}R^{42})$;

or R^1 is absent when z is a double bond

R^5 is selected from the group consisting of

1) C $_{1-6}$ alkyl,
2) =O
3) aryl
4) C_{3-10} cycloalkyl
5) C_{1-6}alkylene-$C(O)R^{11}$,
6) C_{1-6}alkylene-$C(O)R^{13}$
7) $C(O)R^{11}$,
8) $C(O)R^{13}$,
9) $C(O)OR^{11}$,
10) $C(O)OR^{13}$,
11) $C(O)N(R^{11}R^{11})$,
12) $C(O)N(R^{13}R^{13})$,
13) $C(O)N(R^{11}R^{13})$,
14) CN,
15) $NHC(O)R^{11}$,
16) $NHC(O)CF_3$, and
17) $NHC(O)C_{2-6}$alkyl,

or R^1 and R^5, together with atoms to which they are attached, form



where t is 0, 1, 2, or 3, and R^n is selected from the group consisting of hydrogen, -ORP, NRPRq, C(O)NRPRq, or C(O)ORP, wherein RP and Rq are independently selected from the group consisting of C_{1-6} alkyl and aryl;

R^{11} is selected from the group consisting of

1) aryl, and

2) an unsubstituted or substituted heterocyclic ring consisting of a 4-6 membered unsaturated or saturated monocyclic ring with 1, 2, 3 or 4 heteroatom ring atoms selected from the group consisting N, O and S, and a 9- or 10-membered unsaturated or saturated bicyclic ring with 1, 2, 3 or 4 heteroatom ring atoms selected from the group consisting or N, O or S; and

R^{13} is selected from the group consisting of

1) C_{1-6}alkyl,
2) C_{1-6}alkyloxy,
3) C_{1-6}alkenyl,
4) C_{1-6}alkynyl, and
5) CF_3;

R^a, R^b, R^c, R^d, R^e, R^f, R^g, R^h, R^i, R^j, R^k, and R^l are independently selected from the group consisting of:

1) hydrogen,
2) C_1-C_6 alkyl,
3) halogen,
4) aryl,
5) R^{80},
6) C_3-C_{10} cycloalkyl, and
7) OR^4,

said alkyl, aryl, and cycloalkyl being unsubstituted, monosubstituted with R^7, disubstituted with R^7 and R^{15}, trisubstituted with R^7, R^{15} and R^{16}, or tetrasubstituted with R^7, R^{15}, R^{16} and R^{17};

R^4, R^{40}, R^{41}, R^{42}, R^{43}, R^{44}, R^{45}, R^{46}, R^{47}, R^{48}, R^{49}, R^{51}, and R^{52} are independently selected from:

1) hydrogen,
2) C_1-C_6 alkyl,
3) C_3-C_{10} cycloalkyl,
4) aryl,
5) R^{81},
6) CF_3,
7) C_2-C_6 alkenyl, and
8) C_2-C_6 alkynyl,

said alkyl, aryl, and cycloalkyl is unsubstituted, mono-substituted with R^{18}, di-substituted with R^{18} and R^{19}, tri-substituted with R^{18}, R^{19} and R^{20}, or tetra-substituted with R^{18}, R^{19}, R^{20} and R^{21};

R^6, R^{60}, R^{61}, and R^{63} are independently selected from:

1) C_1-C_6 alkyl,
2) aryl,
3) R^{83}, and
4) C_3-C_{10} cycloalkyl;

said alkyl, aryl, and cycloalkyl is unsubstituted, mono-substituted with R^{26}, di-substituted with R^{26} and R^{27}, tri-substituted with R^{26}, R^{27} and R^{28}, or tetra-substituted with R^{26}, R^{27}, R^{28} and R^{29};

R^7, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{26}, R^{27}, R^{28}, and R^{29} are independently selected from:

1) C_1-C_6 alkyl,
2) halogen,
3) OR^{51},
4) CF_3,
5) aryl,
6) C_3-C_{10} cycloalkyl,
7) R^{84},
8) $S(O)_{0-2}N(R^{51}R^{52})$,
9) $C(O)OR^{51}$,
10) $C(O)R^{51}$,
11) CN,
12) $C(O)N(R^{51}R^{52})$,
13) $N(R^{51})C(O)R^{52}$,
14) $S(O)_{0-2}R^{63}$,
15) NO_2, and
16) $N(R^{51}R^{52})$;

R^{80}, R^{81}, R^{83} and R^{84} are independently selected from a group of unsubstituted or substituted heterocyclic rings consisting of a 4-6 membered unsaturated or saturated monocyclic ring with 1, 2, 3 or 4 heteroatom ring atoms selected from the group consisting N, O and S, and a 9- or 10-membered unsaturated or saturated bicyclic ring with 1, 2, 3 or 4 heteroatom ring atoms selected from the group consisting or N, O or S; and

n, p, q, r, and s are independently 0, 1, 2, 3, 4, 5 or 6,
provided that, when R^9 is hydrogen, A is substituted as defined above.

2. A compound of Claim 1, or a pharmaceutically acceptable salt thereof,

wherein

A is an aryl ring selected from phenyl, unsubstituted or substituted as in Claim 1, or a heteroaryl ring, unsubstituted or substituted as in Claim 1, selected from the group consisting of pyridine, pyrimidine, pyrazine, pyridazine, indole, pyrrolopyridine, benzimidazole, benzoxazole, benzothiazole, and benzoxadiazole;

R^2, R^8, R^9 and R^{10} are independently selected from the group consisting of:

1) hydrogen,
2) halogen,
3) OR^{43}, and
4) $(CR^eR^f)_pR^{43}$,

or R^2 and R^8 are independently as defined above, and R^9 and R^{10}, together with the atoms to which they are attached, form the ring



, where R^m is C_{1-6}alkyl; and

R^1 is selected from the group consisting of

1) hydrogen,
2) $(CR^aR^b)_{1-2}R^{40}$
3) $(CR^aR^b)_{1-2}OR^{40}$,
4) $(CR^aR^b)_{1-2}N(R^{40}R^{41})$,
5) $(CR^aR^b)_{1-2}N(R^{40})C(O)OR^{41}$,
6) $(CR^aR^b)_{1-2}N(R^{40})(CR^cR^d)_2N(R^{41})C(O)R^{49}$,
7) $(CR^aR^b)_{1-2}C(O)OR^{40}$,
8) $(CR^aR^b)_{1-2}N(R^{40})(CR^cR^d)_{1-3}R^{41}$, and
9) cyclopropyl,

or R^1 and R^5, together with atoms to which they are attached, form



where t is 0, 1, 2, or 3, and R^n is selected from the group consisting of hydrogen, -ORp, NRpRq, C(O)NRpRq, or C(O)ORp, wherein Rp and Rq are independently selected from the group consisting of C_{1-6} alkyl and aryl.

3. A compound of Claim 2, or a pharmaceutically acceptable salt thereof, wherein R^2, R^8, R^9, and R^{10} are independently selected from the group consisting of hydrogen and $-OR^{43}$.

4. A compound of Claim 3, or a pharmaceutically acceptable salt thereof, wherein A is selected from the group consisting of A is phenyl, fluorophenyl and chlorophenyl.

5. A compound of Claim 4, or a pharmaceutically acceptable salt thereof, wherein

R^1 is selected from the group consisting of C_{1-6}alkyl and C_{3-10} cycloalkyl, or R^1 is absent when z is a double bond;

R^5 is selected from the group consisting of C_{1-6} alkyl, =O, aryl, and C_{3-10} cycloalkyl;

or R^1 and R^5 together with the atoms to which they are attached, form



6. A compound of Claim 5, or a pharmaceutically acceptable salt thereof, selected from the group consisting of

5-(3-fluorophenyl)-3-methoxy-5,5a,6,7,8,9-hexahydro-11H-pyrido[2,1-b]quinazolin-11-one,

(5,6-cis)-5-(3-fluorophenyl)-3-methoxy-11-oxo-5,6,7,8,9,11-hexahydro-5aH-pyrido-[2,1-b]quinazoline-6-carboxylate,

ethyl (5,6-cis)-11-oxo-5-phenyl-5,6,7,8,9,11-hexahydro-5aH-pyrido[2,1-b]quinazoline-6-carboxylate,

7-methoxy-2,3-dimethyl-1-phenyl-2,3-dihydroquinazolin-4(1H)-one,

6-methoxy-4-phenyl-2,3,3a,4-tetrahydropyrrolo[2,1-b]quinazolin-9(1H)-one,

3-methoxy-5-phenyl-5,5a,6,7,8,9-hexahydro-11H-pyrido[2,1-b]quinazolin-11-one,

3-methoxy-5-phenyl-5a,6,7,8,9,10-hexahydroazepino[2,1-b]quinazolin-12(5H)-one,

7-methoxy-2-methyl-4-oxo-1-phenyl-1,4-dihydroquinazolin-1-ium chloride,

2-tert-butyl-7-methoxy-1-phenylquinazolin-4(1H)-one,

2-cyclohexyl-7-methoxy-1-phenylquinazolin-4(1H)-one, and

3-cyclopropyl-7-methoxy-1-phenylquinazoline-2,4(1H,3H)-dione.

7. A method of treating a condition in a mammal, the treatment of which is effected or facilitated by $K_V1.5$ inhibition, which comprises administering a compound of Claim 1 in an amount that is effective at inhibiting $K_V1.5$.

8. A method of Claim 7, wherein the condition is cardiac arrythmia.

9. A method of Claim 8, wherein the cardiac arrythmia is atrial fibrillation.

10. A method of Claim 8, wherein the cardiac arrythmia is selected from the group consisting of atrial flutter, atrial arrhythmia and supraventricular tachycardia.

11. A method of preventing a condition in a mammal, the prevention of which is effected or facilitated by $K_V1.5$ inhibition, which comprises administering a compound of Claim 1 in an amount that is effective at inhibiting $K_V1.5$.

12. A method of Claim 11, wherein the condition is cardiac arrythmia.

13. A method of Claim 12, wherein the cardiac arrythmia is atrial fibrillation.

14. A method of Claim 12, wherein the cardiac arrythmia is selected from the group consisting of atrial flutter, atrial arrhythmia and supraventricular tachycardia.

15. A method of Claim11, wherein the condition is a thromboembolic event.

16. A method of Claim 15, wherein the thromboembolic event is a stroke.

17. A method of Claim 11, wherein the condition is congestive heart failure.

18. A pharmaceutical formulation comprising a pharmaceutically acceptable carrier and the compound Claim 1 or a pharmaceutically acceptable crystal form or hydrate thereof.

19. A pharmaceutical composition made by combining the compound of Claim 1 and a pharmaceutically acceptable carrier.

20. A method of treating cardiac arrythmia comprising administering a compound of Claim 1 with a compound selected from one of the classes of compounds consisting of antiarrhythmic agents having Kv1.5 blocking activities, ACE inhibitors, angiotensin II antagonists, cardiac glycosides, L-type calcium channel blockers, T-type calcium channel blockers, selective and nonselective beta blockers, endothelin antagonists, thrombin inhibitors, aspirin, nonselective NSAIDs, warfarin, factor Xa inhibitors, low molecular weight heparin, unfractionated heparin, clopidogrel, ticlopidine, IIb/IIIa receptor antagonists, 5HT receptor antagonists, integrin receptor antagonists, thromboxane receptor antagonists, TAFI inhibitors and P2T receptor antagonists.

21. A method for inducing a condition of normal sinus rhythm in a patient having atrial fibrillation, which comprises treating the patient with a compound of Claim 1.

22. A method for treating tachycardia in a patient which comprises treating the patient with an antitachycardia device in combination with a compound of Claim 1.